Prostate Cancer Clinical Trials
The resources on this page can direct you to clinical trials that are currently open for enrollment in your local area, as well as across the country. If you are considering a clinical trial, speak to your doctor about the potential benefits of participating in a trial so you can make an informed decision that is best for you.
Prostate Cancer Clinical Trials Consortium
The Prostate Cancer Clinical Trials Consortium (PCCTC) is a clinical research group sponsored by the Prostate Cancer Foundation and the Department of Defense Prostate Cancer Research Program (PCRP), with its Coordinating Center headquartered at Memorial Sloan Kettering Cancer Center. The PCCTC is currently composed of 15 participating clinical research sites and 32 affiliated clinical research sites.
Visit the PCCTC site for trial information: www.pcctc.org
Open Trials
For a complete list of open trials in the United States, please visit:
Prostate cancer is the second most diagnosed cancer in men worldwide.
Even though some therapies for prostate cancer called androgen receptor signaling inhibitors (ARSIs) have been shown to help, it is common for patients to develop a resistance to these types of medications. This means that for some men with prostate cancer, treatment stops working. Because of this, continuing research is so important.
A new study for adults with prostate cancer is investigating a study drug called ONCT-534. ONCT-534 is designed to work differently, and doctors want to learn if it is safe and useful for individuals with metastatic castration-resistant prostate cancer (mCRPC).
To be eligible for this study, you must*:
• Be at least 18 years of age
• Have mCRPC
• Have cancer that has come back or stopped responding to treatment after taking certain ARSIs
*This is not a complete list of study requirements. If you are interested, the study doctor will review the full eligibility criteria with you.
To learn more about this study, visit https://www.clinicaltrials.gov/study/NCT05917470
Do you have prostate cancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. In the EA8191/INDICATE study, all participants will receive the usual treatment for prostate cancer that recurs after surgery, which is radiation therapy (RT) to the prostate bed and pelvic lymph nodes, combined with short-term (6 months) androgen deprivation therapy (STAD), also sometimes referred to as hormone therapy. In addition:
– Some patients will receive additional PET imaging, depending on the results of their initial PET scan.
– Some patients will also receive a type of hormone therapy called apalutamide, which is approved by the FDA for treatment of your prostate cancer.
– Some patients, depending on the results of their initial PET scan, will receive metastasis-directed radiation therapy.
To decide which of these approaches is better, doctors on the study team will be looking to see if your cancer responds, and if it returns again, how much time passes after your treatment before it returns.
To learn more about this study and to find out if you may be eligible, please visit: https://www.clinicaltrials.gov/study/NCT04423211
ClinicalTrials.gov identifier: NCT04423211
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Merck is conducting this clinical trial to find out if the investigational medication pembrolizumab in combination with abiraterone and prednisone is safe and works to slow down or stop the growth of metastatic Castrate Resistant Prostate Cancer (mCPRC). Pembrolizumab is a type of immunotherapy, which may help the body’s immune system attack cancer cells. This trial is currently enrolling patients with mCRPC who have not received chemotherapy for mCRPC and have either not had prior second generation hormonal manipulation for mCRPC, or have previously been treated with enzalutamide for mCRPC and failed treatment or has become intolerant of the drug. Additional eligibility criteria will apply. Click here to learn more about this trial on the sponsor’s website.
To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT02861573
ClinicalTrials.gov Identifier: NCT02861573
MVT-601-049
Myovant Sciences is conducting a clinical study to learn about the safety and tolerability of relugolix in combination with medications approved for use in combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic castrate-sensitive prostate cancer (mCSPC), non-metastatic castrate-resistant prostate cancer (nmCRPC) and metastatic castrate-resistant prostate cancer (mCRPC).
Relugolix is an oral, FDA-approved medication. The clinical study will have three parts. Patients with advanced prostate cancer will participate in only one of the three parts of the clinical study.
Additional open trials can be found by going to:
